Combined assessment of polymorphisms in the LHCGR and FSHR genes predict chance of pregnancy after in vitro fertilization.

Lindgren, Ida; Bååth, Maria; Uvebrant, Tina; Dejmek, Annika; Kjaer, Louise; Henic, Emir; Bungum, Mona; Bungum, L; Cilio, Corrado; Leijonhufvud, Irene; Skouby, S; Andersen, C Yding; Lundberg Giwercman, Yvonne

Published in:
Human Reproduction

DOI:
10.1093/humrep/dev342

Published: 2016-01-01

Document Version:
Peer reviewed version (aka post-print)

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Combined assessment of polymorphisms in the \textit{LHCGR} and \textit{FSHR} genes predict chance of pregnancy after \textit{in vitro} fertilization

Running title: \textit{LHCGR} and \textit{FSHR} variants predict IVF outcome

Lindgren I, M.Sc.\textsuperscript{1*}, Bååth M, M.Sc.\textsuperscript{1}, Uvebrant K, M.Sc.\textsuperscript{2}, Dejmek A, M.D.\textsuperscript{3}, Kjaer L, M.Sc.\textsuperscript{1}, Henic E, M.D.\textsuperscript{4}, Bungum M, Ph.D.\textsuperscript{4}, Bungum L, M.D.\textsuperscript{5}, Cilio C, M.D.\textsuperscript{2}, Leijonhufvud I, B.Sc.\textsuperscript{4}, Skouby S, M.D.\textsuperscript{5}, Yding Andersen C, Ph.D.\textsuperscript{6}, and Lundberg Giwercman Y, Ph.D.\textsuperscript{1}

\textsuperscript{*}Joint first authorship

* Corresponding author: Ida Lindgren, Department of Translational Medicine, Molecular Genetic Reproductive Medicine, Lund University, Clinical Research Centre, Jan Waldenströms gata 35, Building 91, Plan 10, SE 20502 Malmö, Sweden.

Tel: +46 40 391120; fax: +46 40 391222; e-mail: Ida.Lindgren@med.lu.se

1. Department of Translational Medicine, Molecular Genetic Reproductive Medicine, Lund University, Clinical Research Centre, Jan Waldenströms gata 35, Building 91, Plan 10, SE 20502 Malmö, Sweden

2. Department of Clinical Sciences, Cellular Autoimmunity Unit, Lund University, Clinical Research Centre, Jan Waldenströms gata 35, Building 91, Plan 10, SE 20502 Malmö, Sweden

3. Department of Clinical Pathology, University and Regional Laboratories, Skåne University Hospital, Jan Waldenströms gata 59, SE 20502 Malmö, Sweden
4. Reproductive Medicine Centre, Skåne University Hospital, Jan Waldenströms gata 47, Plan 3, SE 20502 Malmö, Sweden

5. Department of Obstetrics and Gynecology, Herlev Hospital, Herlev Ringvej 75, 2730 Herlev, Denmark

6. Laboratory of Reproductive Biology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen, Denmark
Abstract

**Study question:** Can gonadotropin receptor variants separately or in combination, be used for prediction of pregnancy chances in *in vitro* fertilization (IVF) trials?

**Summary answer:** The luteinizing hormone receptor (*LHCGR*) variant N312S and the follicle stimulating hormone receptor (*FSHR*) variant N680S can be utilized for prediction of pregnancy chances in women undergoing IVF.

**What is known already:** The *FSHR* N680S polymorphism has been shown to affect the ovarian response in response to gonadotropin treatment, while no information is currently available regarding variants of the *LHCGR* in this context.

**Study design, size, duration:** Cross sectional study, duration from September 2010 to February 2015. Women undergoing IVF were consecutively enrolled and genetic variants compared between those who became pregnant and those who did not. The study was subsequently replicated in an independent sample. Granulosa cells from a subset of women were investigated regarding functionality of the genetic variants.

**Participants/materials, setting, methods:** Women undergoing IVF (n=384) were enrolled in the study and genotyped. Clinical variables were retrieved from medical records. For replication, an additional group of n=233 women was utilised. Granulosa cells from n=135 women were isolated by flow cytometry, stimulated with Follitropin alpha or Menotropin, and the downstream targets cAMP and IP₃ measured with ELISA.

**Main results and the role of chance:** Women homozygous for serine (S) in both polymorphisms displayed higher pregnancy rates than women homozygous asparagine (N) (OR=14.4, 95% CI: [1.65, 126], p=0.016). Higher pregnancy rates were also evident for women carrying *LHCGR* S312, regardless of *FSHR* variant (OR=1.61, 95% CI: [1.13, 2.29], p=0.008).
These women required higher doses of FSH for follicle recruitment than women homozygous N (161 IU vs. 148 IU, p=0.030). When combining the study cohort with the replication cohort (n=606), even stronger associations with pregnancy rates were noted for the combined genotypes (OR=11.5, 95% CI: [1.86, 71.0], p=0.009) and for women carrying LHCGR S312 (OR=1.49, 95% CI: [1.14, 1.96], p=0.004). A linear significant trend with pregnancy rate and increasing number of G alleles was also evident in the merged study population (OR=1.34, 95% CI: [1.10, 1.64], p=0.004). A lower cAMP response in granulosa cells was noted following Follitropin alpha stimulation for women homozygous N in both polymorphisms, compared to women with other genotypes (0.901 pmol cAMP/mg total protein vs. 2.19 pmol cAMP/mg total protein, p=0.035).

**Limitations, reasons for caution:** Due to racial differences in LHCGR genotype distribution, these results may not be applicable for all populations.

**Wider implications of the findings:** Despite that more than 250,000 cycles of gonadotropin stimulations are performed annually worldwide prior to IVF, it has not been possible to predict neither the pregnancy outcome, nor the response to the hormone with accuracy. If LHCGR and FSHR variants are recognized as biomarkers for chance of pregnancy, more individualized and thereby more efficient treatment modalities can be developed.

**Study funding, competing interest(s):** This work was supported by Interreg IV A, EU (grant 167158) and ALF governments grant (F2014/354). Merck-Serono (Darmstadt, Germany) supported the enrolment of the subjects. The authors declare no conflict of interest.

**Keywords:** LHCG receptor, FSH receptor, in vitro fertilization, polymorphism.
Introduction

About 15% of all couples experience involuntary childlessness (World Health Organization, 2000). This number is expected to increase as a combination of socially related issues with prolonged time to start a family and increased access to assisted reproductive techniques also in rapidly growing economies as in Asia.

It has for a long time been known that follicle-stimulating hormone (FSH) plays a central role in the endocrine regulation of female as well as male gametogenesis. Follicle-stimulating hormone mediates its effect via the FSH receptor (FSHR) located on the cell membrane of ovarian granulosa cells (Camp et al., 1991) from where FSH drives follicular maturation (McNeilly et al., 1991) and estrogen production (Nordhoff et al., 2011). The FSHR belongs to the G protein-coupled receptor family and hence signals through the classical $G_{\alpha s}$/3'-5' cyclic adenosine monophosphate (cAMP)/protein kinase A pathway (Means et al., 1974), but also through for example the adapter protein containing pleckstrin homology domain, phosphotyrosine binding domain and leucine zipper motif (APPL1)/inositol 1,4,5,-triphosphate (IP$_3$) signaling pathway (Thomas et al., 2011).

The FSHR gene is located on chromosome 2 and consists of ten exons. Exon 10 holds five single nucleotide polymorphisms (SNPs) in the coding region, of which the one in amino acid position 680 (N680S; rs6166), in the intracellular domain, is the most thoroughly studied (Simoni et al., 1999; Gromoll and Simoni, 2005). In Caucasian populations approximately 30% are homozygous for asparagine (N), 50% are heterozygous, and 20% are homozygous for serine (S) (Kuijper et al., 2010; Lindgren et al., 2012). It has been proposed that women homozygous for FSHR S680 require a higher dose exogenous FSH prior to IVF than those with FSHR N680, in
order to achieve successful ovarian stimulation (Perez Mayorga et al., 2000; Sudo et al., 2002). These women also seem to have longer menstrual cycles and have a higher risk for severe ovarian hyperstimulation syndrome compared with women with other genotypes (Daelemans et al., 2004). In a previous study it was also evident that women homozygous for FSHR N680 more often became pregnant after IVF, compared to women with other genotypes (Jun et al., 2006). Altogether, these observations indicate that individuals who are carriers of FSHR S680 may have decreased FSHR response compared with carriers of one or two copies of FSHR N680. Furthermore, it was recently suggested that intracellular cAMP production was faster in human granulosa cells from homozygous carriers of FSHR N680 than in women homozygous for FSHR S680 when stimulated with FSH in vitro (Casarini et al., 2014). However, this study only comprised four women.

Luteinizing hormone (LH) mediates its effect through the LH/human chorionic gonadotropin (hCG) receptor (LHCGR) located on cell membranes of granulosa and theca cells (Camp et al., 1991). When LH binds to LHCGR on theca cells, androstenedione and subsequently estradiol production is triggered (Short, 1962). Like the FSHR, the LHCGR also belongs to the G protein-coupled receptor family and holds seven transmembrane helices. The LHCGR gene is located on chromosome 2, close to the FSHR gene, and contains 11 exons. Of the polymorphisms in the LHCGR gene, the N312S polymorphism (rs2293275) in exon 10 is one of the most studied. Approximately 18% of Caucasian populations are homozygous for the A allele of the LHCGR N312S polymorphism encoding N, 49% are heterozygous, and 33% are homozygous for the G allele, encoding S (Valkenburg et al., 2009). The LHCGR N312S polymorphism is located near a glycosylation site which indicates that variations in the sequence could affect sensitivity. A few
cohort studies have proposed that the N variant may render the LHCGR more sensitive (Piersma et al., 2007; Simoni et al., 2008). The LHCGR N312S polymorphism has also been linked to polycystic ovary syndrome (PCOS), where heterozygous women had two-fold increased risk of PCOS and those homozygous for N had a three-fold increased risk in a Sardinian population (Capalbo et al., 2012).

Since the endocrine regulation of the process leading to the creation of a competent oocyte and thereby female fertility is dependent on both FSH and LH, the objective of the current study was to investigate if described polymorphisms in the FSHR and LHCGR genes, separately and in combination, impact IVF outcomes and clinical parameters in IVF trials. In addition, since FSHR and LHCGR are expressed on granulosa cells, the downstream hormonal effects were investigated by culturing and stimulating these cells in vitro.
Materials & Methods

Subjects

Women undergoing IVF at the Reproductive Medicine Centre, Skåne University Hospital, Malmö, Sweden (n=384) were consecutively enrolled in the study from September 2010 to February 2015. Inclusion criteria were regular menstruation cycle of 21-35 days, bilateral ovaries, body mass index (BMI) <30 kg/m\(^2\), younger than 40 years of age, and non-smokers. The women were between 22 and 39 years of age (mean: 32.0±3.82) on the day of follicular fluid aspiration (Table I). A venous blood sample was drawn for DNA extraction with subsequent FSHR and LHCGR genotyping. Follicular fluid was collected for subsequent granulosa cell isolation from n=135 women while undergoing oocyte retrieval. Clinical data for the women were retrieved from medical records. In n=11 women, BMI was missing and these women were hence excluded when associating genotype with clinical parameters, resulting in a total of n=373. In n=30 women, data regarding baseline FSH values were missing, and these women were therefore also excluded when associating genotype with baseline FSH values. Additionally, in n=37 women, data regarding cycle length was missing (although the cycle length of these women were in the normal range) and hence these women were excluded when associating cycle length with genotype.

An independent population of n=233 women was enrolled a posteriori in order to validate pregnancy associations in the study cohort. These women underwent IVF at the same medical unit as the first cohort from the start of year 2007 until June 2015, and the inclusion criteria were the same as for the first study cohort. The women were between 20 and 40 years of age (mean: 32.5±3.93) on the day of follicular fluid aspiration (Table I). The BMI values for these women
were not recorded, and therefore this parameter was missing for this population. However, in order to undergo an IVF treatment at this clinical unit, BMI has to be <30 kg/m². Clinical data regarding age and IVF parameters were retrieved from medical records.

**Patient treatment**

Ovarian stimulation was performed according to either a short antagonist protocol using the gonadotropin-releasing hormone (GnRH) antagonist Ganirelix (Orgalutran, Organon [Ireland] Ltd, Dublin, Ireland) or a standard long protocol using the GnRH agonist Nafarelin (Synarela, Pfizer Ab, Sollentuna, Sweden) (Table II). Ovarian hyperstimulation was carried out using individually set, flexible doses of either Follitropin alpha (GONAL-f, Merck-Serono, Darmstadt, Germany), Follitropin beta (Puregon, Organon [Ireland] Ltd), Urofollitropin (Fostimon, Institut Biochimique SA [IBSA], Lugano, Switzerland), or Menotropin (Menopur, Ferring GmbH, Kiel, Germany). The progression of follicle development was monitored by vaginal ultrasound on day 6-8 of stimulation, and if needed the individual doses were adjusted. When three or more follicles were confirmed by ultrasound, hCH was administered and 35 h later oocyte retrieval was performed.

**Genotyping of FSHR and LHCGR**

Genomic DNA was extracted from peripheral leukocytes using standard procedures, and the SNP at amino acid position 680 in the FSHR was analyzed by allele-specific PCR as previously described (Lindgren et al., 2012). The PCR results were confirmed by direct sequencing of 20 samples on an eight-capillary Applied Biosystems sequencing gear (Applied Biosystems, Stockholm, Sweden). The N312S polymorphism in the LHCGR was analyzed by PCR
amplification followed by direct sequencing. Polymerase chain reactions were performed in a total volume of 50 µL containing 0.4 µM of the forward primer 5´-GTTGACCATGTGACTGGGA and 0.4 µM of the reverse primer 5´-ACTCTCTCCTCAGGAAGCAT (Invitrogen, Stockholm, Sweden), 10 mM Tris-HCl (AppliChem GmbH, Gatersleben, Germany) pH 9.1, 45 mM KCl (ICN Biomedicals INC., Aurora, OH, USA), 0.01% w/v Tween 20 (Scharlau Chemie S.A., Barcelona, Spain), 1.5 mM MgCl₂ (Sigma-Aldrich Sweden AB, Stockholm, Sweden), 200 µM of each dNTP (Fermentas, Sankt Leon-Rot, Germany), 1 U Dynazyme™ II DNA polymerase (Thermo Fisher Scientific Inc., Waltham, MA, USA) and 200 ng template DNA. The amplification program was initiated by a denaturation step at 96ºC for 10 min, followed by 37 amplification cycles, each consisting of denaturation at 96ºC for 1 min, annealing at 61ºC for 30 sec and elongation at 72ºC for 3 min. A final elongation at 72ºC for 7 min was applied. The PCR product was purified and directly sequenced on an eight-capillary Applied Biosystems sequencing gear (Applied Biosystems).

Hormonal analysis

For endocrine serum analysis, blood samples were drawn between 8 and 10 a.m. Estradiol (E2), FSH, and LH was measured using an electrochemiluminiscence immunoassay (Cobas-Roche, Mannheim, Germany) at the routine clinical chemistry laboratory at Skåne University Hospital (Lund, Sweden). The sensitivities of the assays were 18.4 pmol/L for E2 and 0.10 IU/L for FSH and LH. The coefficients of variances (CV) for E2 were 7% at 289 pmol/L and 4% at 2711 pmol/L, for FSH 3% at 5 IU/L and 3% at 41 IU/L, and for LH 3% at 5 IU/L and 2% at 37 IU/L.

Isolation of granulosa cells from follicular fluid
Follicular fluid from the right and left ovary of each subject was aspirated and granulosa cell aggregates were manually identified and placed in phenol-red free Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco Invitrogen, Carlsbad, CA, USA), supplemented with 10% fetal bovine serum (FBS; Biological Industries, Beit HaEmek, Israel) and 1% 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; Mediatech Inc., Manassas, VA, USA), and subsequently filtered through a 70 µm cell strainer (Becton Dickinson Biosciences, San José, CA, USA) in order to concentrate the granulosa cells and to discard most of the single cells e.g. red blood cells, leukocytes, and debris. The aggregated cells were washed with RPMI medium followed by dispersion through the cell strainer using the back of a syringe until there were no visible granulosa cell aggregates. The filtered cells were centrifuged for 10 min at 300xg. The supernatant was discarded and the cell pellet was resuspended in supplemented RPMI medium.

Cell sorting

To isolate granulosa cells from follicular fluid CD99 was used as a marker. In order to avoid non-specific binding of the antibodies used for granulosa cell sorting, Fc receptor blocking was carried out with TrueStain (BioLegend, London, UK) for 5 min prior to antibody staining with anti-CD45 PerCP (BioLegend) and anti-CD99 PE (eBioscience, San Diego, CA, USA). The granulosa cells were mixed gently and incubated for 15 min in darkness at room temperature. Stained cells were filtered through a 50 µm filcon with syringe fitting (Biogenetics, Padova, Italy) and washed in supplemented RPMI medium. Filtered cells were centrifuged at 430xg for 5 min and resuspended in 200 µL supplemented RPMI medium. Seven-Amino actinomycin D (7-AAD) (BioLegend) was added 5 min prior to flow cytometry acquisition and cell sorting. The samples were subsequently acquired and sorted in a FACS Aria (Becton Dickinson Biosciences).
The gating strategy for definition of viable granulosa cells was an acquisition gate based on side scatter (SSC) and forward scatter (FSC), including cells with high granularity and excluding cell debris, dead cells and leukocytes (7-AAD and CD45 positive cells). Remaining cells were gated on the most granular and CD99 positive cells, which were defined as viable granulosa cells and sorted into supplemented RPMI medium containing 55% FBS. Flow cytometry data were analyzed using FlowJo (TreeStar Inc., Ashland, OR, USA).

Identification of granulosa cells

Specimens from three different, randomly selected patients (unsorted and sorted cells) were morphologically evaluated at the Department of Pathology and Cytology, Skåne University Hospital, Malmö, Sweden. The cells, which were kept in R10 medium, were centrifuged at 760×g for 10 min. The supernatant was decanted and Becton Dickinson Cytorich™ (red) was added. The tubes were left at 4°C for at least 30 min to ensure optimal fixation of the cells, before centrifugation at 760×g for 10 min. The supernatant was decanted and the cell pellet re-suspended in deionized water. The cell suspension was added to pre-prepared cell chambers (Settling chamber 240, TriPath Imaging, Becton Dickinson Diagnostics, Sparks, NV, USA), placed on pre-coated slides (SurePath precoat slides, TriPath Imaging, Becton Dickinson Diagnostics) and left for 15 min to allow the cells to adhere to the slides. The slides were subsequently fixed in 95% ethanol for at least 30 min and stained with Htx-eosin (Histolab Products AB, Gothenburg, Sweden) according to routine cyto-staining procedures before examination with an Olympus BH-2 microscope (Olympus Corporation, Center Valley, Pa, USA) and morphological evaluation. Granulosa cells and other cell types were counted in
randomly chosen high power (objective lens ×40, ocular lens ×10) microscopic fields until
approximately 300 cells were counted.

Culture and granulosa cell activity

Approximately 75,000 human granulosa cells per well were cultured into 24-well plates in
supplemented RPMI medium with 0.02 mg/mL gentamicin (PAA Laboratories, Pasching,
Austria) for 2-3 days before incubation in serum-free RPMI medium (containing HEPES and
gentamicin) for 1 h at 37°C, 5% CO₂, in the absence or presence of 150 mIU/mL Follitropin
alpha (GONAL-f [Merck-Serono]) or 150 mIU/mL Menotropin (Menopur [Ferring GmbH]). The
cell culture medium was aspirated and centrifuged for 20 min, 1000×g at room temperature.
Endogenous phosphodiesterases were heat inactivated for 5 min at 95°C. Cells were lysed with
Passive lysis buffer (Promega, Stockholm, Sweden). Experiments were carried out in duplicates
whenever a sufficient number of granulosa cells were retrieved. The FSHR as well as the
LHCGR activity through the Gαs/cAMP/protein kinase A pathway was measured in the cell
culture medium using a cAMP ELISA kit (ENZO Life Sciences, Lausen, Switzerland), whereas
activity through the IP₃-signaling pathway was measured in 55 randomly selected women using
an IP₃ ELISA kit (Cusabio, Wuhan, China). All results were adjusted for total protein
concentrations in the cell lysates using Pierce BCA (bicinchoninic acid) protein assay reagent
(Thermo Fisher Scientific Inc.), as well as adjusted for basal activity in unstimulated cells from
each patient.

Statistical analysis
Allele frequencies of the two polymorphisms were analyzed in comparison to control populations using $q^2$ test. The \textit{LHCGR} N312S polymorphism was tested against a normal population of 2996 Caucasians (Piersma \textit{et al.}, 2007), and the \textit{FSHR} N680S polymorphisms against a normal population of 1431 Caucasians (Kuijper \textit{et al.}, 2010). Linkage between the two polymorphisms was investigated by calculation of linkage disequilibrium, with data extracted from phase 1 data from the 1000 genomes project (ENSEMBL).

All residuals were tested for normal distribution in the Kolmogorov–Smirnov test, and log transformed if lack of Gaussian distribution. Calculations for associations with clinical parameters among genotype groups were carried out by comparing each genotype group separately (i.e. N680N vs. N680S vs. S680S for the \textit{FSHR}; N312N vs. N312S vs. S312S for the \textit{LHCGR}). Comparisons of age, BMI, cycle length, baseline hormones, hormonal doses given prior to IVF, and follicle and oocyte outcomes among genotype groups were carried out using a univariate analysis of variance. Comparisons of incidence of endometriosis and polycystic ovary syndrome, and occurrence of embryo transfer among genotype groups were carried out using a $q^2$ test. Comparisons of pregnancy outcomes among genotype groups were carried out using a $q^2$ test and logistic regression. In order to evaluate a combined effect of the \textit{FSHR} and \textit{LHCGR} on pregnancy outcomes in the merged study group, the G alleles from both polymorphisms were considered (0-4 G alleles) and a trend of the increased number of G alleles for the \textit{FSHR} polymorphism and the \textit{LHCGR} polymorphism analyzed using logistic regression. Age (as a continuous variable), and BMI ($\leq 25$ and $>25$) were considered as confounding factors when analyzing differences in cycle length, baseline hormones, hormonal doses, and follicle and oocyte counts between genotypes. Age, BMI, use of intracytoplasmic sperm injection (ICSI),
type of stimulation protocol, and type of hormonal agent used (Follitropin or Menotropin) were considered as confounding factors when analyzing differences in pregnancy outcomes. Analysis concerning pregnancy outcome was also performed, using the same covariates, after exclusion of the 13 women who were diagnosed with PCOS.

In order to evaluate a combined effect of the FSHR and LHCGR polymorphisms on cAMP and IP$_3$ concentrations in cell culture supernatants from granulosa cells, the G alleles from both polymorphisms were added (0-4 alleles) and a trend of the increased number of G alleles for the FSHR polymorphism and the LHCGR polymorphism was analyzed using linear regression. Each polymorphism was also analyzed separately. In addition, we used a univariate analysis of variance in order to compare individual groups of combined polymorphisms. Age (as a continuous variable) was considered as a confounding factor when analyzing differences in cAMP and IP$_3$ concentrations in cell culture supernatants.

Since the study was performed on candidate genes, no correction for mass significance was done (Cordell and Clayton, 2005).

Data was analyzed using SPSS software version 22 (SPSS Inc., Chicago, IL, USA). A p-value of <0.05 was considered statistically significant. Minitab 12.21 (Minitab Inc., State College, PA, USA) was used when calculating exact binomial proportion confidence interval of purity of sorted granulosa cells.

*Ethical approval*
Written informed consent was obtained from all participants. The study was approved by the ethical committee board at Lund University, Sweden.
Results

Genotyping

Allele frequencies for the FSHR N680S polymorphism were 55% for the A allele, encoding asparagine, and 45% for the G allele, encoding serine. Genotype distribution was 28% homozygous N, 55% heterozygous, and 17% homozygous S. For the LHCGR N312S polymorphism, allele frequencies were 41% A, encoding asparagine, and 59% G, encoding serine. The genotype distribution was 17% homozygous N, 47% heterozygous, and 36% homozygous S (Table I). There was no difference in FSHR N680S allele frequency between the study population and a population previously reported (Kuijper et al., 2010) (p=1), or in LHCGR N312S allele frequency between the study and the general population (Piersma et al., 2007), (p=0.554). The allele frequencies of both polymorphism were in Hardy-Weinberg equilibrium, $x^2=0.06$, $p>0.05$ for LHCGR N312S and $x^2=1.29$, $p>0.05$ for FSHR N680S. The two polymorphisms are in linkage equilibrium, $D'=0.042$, $r^2=0.0015$.

In the second study population the allele frequencies for the FSHR N680S polymorphism were 59% for the A allele and 41% for the G allele. Genotype distribution was 34% homozygous N, 50% heterozygous, and 16% homozygous S. For the LHCGR N312S polymorphism, allele frequencies were 36% for the A allele and 64% for the G allele. Genotype distribution was 15% homozygous N, 43% heterozygous, and 42% homozygous S (Table I). There were no differences in the allele frequencies between the replication population and the first study population (p=0.191 for FSHR S680N and p=0.080 for LHCGR N312S) and altogether, the allele frequencies of both polymorphisms were in Hardy-Weinberg equilibrium, $x^2=0.52$, $p>0.05$ for LHCGR N312S and $x^2=0.11$, $p>0.05$ for FSHR N680S.
Clinical parameters and IVF outcome

LHCGR N312S

For the LHCGR N312S polymorphism, no differences regarding background characteristics were found between women with N312 or S312, except for a marginal difference in age (Table I). Women homozygous for N received lower mean daily as well as total dose of FSH during IVF treatment. A trend towards higher pregnancy rates for women carrying LHCGR S312 was found (Table I, Fig IA and B), and using a logistic regression model, a statistically significant association was evident (unadjusted: OR= 1.43, 95% CI: [1.03, 1.99], p=0.033; adjusted: OR=1.57, 95% CI: [1.11, 2.22], p=0.011; Fig IA). In women who received embryo transfer, the same difference was found (unadjusted: OR=1.46, 95% CI: [1.03, 2.06], p=0.033; adjusted: OR=1.59, 95% CI: [1.10, 2.29], p=0.013, Fig IB).

Analysis performed after exclusion of PCOS patients resulted in slightly stronger associations: (unadjusted: OR= 1.44, 95% CI: [1.03, 2.01], p=0.032; adjusted: OR=1.61, 95% CI: [1.13, 2.29], p=0.008). In women who received embryo transfer, the same difference was found (unadjusted: OR=1.46, 95% CI: [1.04, 2.07], p=0.031; adjusted: OR=1.60, 95% CI: [1.11, 2.31], p=0.012).

A trend, however not significant, towards higher pregnancy rates for carriers of LHCGR S312 was also found in the replication population of n=233 women (unadjusted: OR=1.36, 95% CI: [0.881, 2.10], p=0.165; adjusted: OR=1.27, 95% CI: [0.798, 2.00], p=0.316). A weak trend was also found among women receiving embryo transfer (unadjusted: OR=1.36, 95% CI: [0.878, 2.11], p=0.168; adjusted: OR=1.27, 95% CI: [0.795, 2.03], p=0.316).
When merging the first study population with the second validation group, in total n=606 women, a higher pregnancy rate was evident for \textit{LHCGR} S312 carriers (Table I; unadjusted: OR=1.40, 95% CI: [1.07, 1.81], p=0.013; adjusted: OR=1.49, 95% CI: [1.14, 1.96], p=0.004). A higher pregnancy rate was also found among those receiving embryo transfer (unadjusted: OR=1.39, 95% CI: [1.07, 1.83], p=0.016; adjusted: OR=1.50, 95% CI: [1.13, 1.99], p=0.005).

\textit{FSHR N680S}

A weak, however not significant, trend towards higher pregnancy rates was also noticed for carriers of S in the \textit{FSHR} N680S polymorphism (unadjusted: OR=1.14, 95% CI: [0.810, 1.61], p=0.452, adjusted: OR=1.11, 95% CI: [0.746, 1.60], p=0.577, Fig IC). There was no significant difference in women who received embryo transfer (unadjusted: OR=1.13, 95% CI: [0.792, 1.61], p=0.499; adjusted: OR=1.08, 95% CI: [0.774, 1.60], p=0.679; Fig ID) or in other clinical variables analyzed in relation to \textit{FSHR} N680S.

Analysis performed after exclusion of PCOS patients displayed very similar results (unadjusted: OR=1.14, 95% CI: [0.811, 1.61], p=0.443; adjusted: OR=1.10, 95% CI: [0.769, 1.58], p=0.597). There was no significant difference among those who received embryo transfer (unadjusted: OR=1.13, 95% CI: [0.786, 1.61], p=0.519; and adjusted: OR=1.08, 95% CI: [0.741, 1.57], p=0.698) or in other clinical variables analyzed in relation to \textit{FSHR} N680S.

Also in the replication population of n=233 women, a weak, but not significant trend towards higher pregnancy rates was found for carriers of \textit{FSHR} S680 (unadjusted: OR=1.24, 95% CI: [0.810, 1.90], p=0.321; adjusted: OR=1.20, 95% CI: [0.752, 1.91], p=0.445). A weak trend
towards higher pregnancy rates among FSHR S680 carriers was also present for those receiving embryo transfer (unadjusted: OR=1.24, 95% CI: [0.808, 1.91], p=0.323; adjusted: OR=1.17, 95% CI: [0.729, 1.88], p=0.514).

When combining the first study population with the second group (n=606), a weak trend, however not significant, towards higher pregnancy rates for FSHR S680 was evident (unadjusted: OR=1.18, 95% CI: [0.906, 1.54], p=0.216; adjusted: OR=1.17, 95% CI: [0.889, 1.55], p=0.260). A non-significant trend towards higher pregnancy rates among FSHR S680 carriers was also observed for women receiving embryo transfer (unadjusted: OR=1.19, 95% CI: [0.903, 1.56], p=0.218; adjusted: OR=1.17, 95% CI: [0.878, 1.55], p=0.288).

**LHCG N312S and FSHR N680S combined**

When analyzing the two polymorphisms combined, a higher pregnancy rate was found for women homozygous for S in both polymorphisms (n=23) compared to those homozygous for N (n=20) (unadjusted: OR=5.79, 95% CI: [1.07, 31.1], p=0.041; adjusted: OR=14.4, 95% CI: [1.65, 126], p=0.016, Fig IIA). The same pattern was found in women who received embryo transfer (unadjusted: OR=6.55, 95% CI: [1.18, 36.3], p=0.032, adjusted: OR=25.7, 95% CI: [1.95, 340], p= 0.014; Fig IIB).

In the independent sample of n=233 women, a tendency towards an association was found for higher pregnancy rates among women homozygous for S in both polymorphisms (n=12) compared to women homozygous for N in both polymorphisms (n=10) (unadjusted: OR=3.00, 95% CI: [0.260, 34.6], p=0.378; adjusted: OR=3.23, 95% CI: [0.103, 101], p=0.505). A similar
association was found in women who received embryo transfer (unadjusted: OR=3.38, 95% CI: [0.290, 39.3], p=0.332, adjusted: OR=3.37, 95% CI: [0.110, 103], p=0.486).

In the merged study population, women homozygous for S (n=35) had higher pregnancy rate than those homozygous for N (n=30) (unadjusted: OR=4.70, 95% CI: [1.18, 18.7], p=0.028; adjusted: OR=11.5, 95% CI: [1.86, 71.0], p=0.009). The same pattern was found in women who received embryo transfer (unadjusted: OR=5.26, 95% CI: [1.30, 21.3], p=0.020; adjusted: OR=11.5, 95% CI: [1.89, 69.9], p=0.008). A linear significant trend with pregnancy rate and increasing number of G alleles was also noted in the merged study population (unadjusted: OR=1.30, 95% CI: [1.08, 1.58], p=0.007; adjusted: OR=1.34, 95% CI: [1.10, 1.64], p=0.004, Fig IIIA). The same was also true for women receiving embryo transfer (unadjusted: OR=1.30, 95% CI: [1.07, 1.58], p=0.009; adjusted: OR=1.33, 95% CI: [1.09, 1.63], p=0.005, Fig IIIB).

Granulosa cell stimulation

A distinct and viable granulosa cell population was isolated by fluorescence activated cell sorting (FACS), consisting of 97.8% (95% CI: [96.6%, 98.6%]) granulosa cells (Table III, Fig IV).

Regarding the FSHR N680S and LHCGR N312S polymorphisms, no differences in response to Follitropin alpha or Menotropin were observed in the induction of cAMP or IP$_3$ production (Table IV). A combination of the two polymorphisms showed no linear association between genotype and induction of cAMP following either Follitropin alpha stimulation (unadjusted: $\beta$=0.247, 95% CI: [-0.070, 0.563], p=0.125; adjusted: $\beta$=0.247, 95% CI: [-0.071, 0.565], p=0.126, Fig VA) or Menotropin stimulation (unadjusted: $\beta$=-0.037, 95% CI: [-0.312, 0.238], p=0.788; adjusted: $\beta$=-0.054, 95% CI: [-0.334, 0.225], p=0.701, Fig VB). Following Follitropin
alpha stimulation, the group of women homozygous N in both polymorphism displayed lower mean cAMP levels compared to others (unadjusted: 0.901 pmol cAMP/mg total protein vs. 2.19 pmol cAMP/mg total protein, p=0.034; adjusted: 0.901 pmol cAMP/mg total protein vs. 2.19 pmol cAMP/mg total protein, p=0.035, Fig VA). Furthermore, no linear association between genotype combinations and induction of IP3 following either Follitropin alpha stimulation (unadjusted: β=-0.024, 95% CI: [-0.153, 0.106], p=0.714; adjusted: β=-0.025, 95% CI: [-0.158, 0.109], p=0.709, Fig VC) or Menotropin stimulation (unadjusted: β=0.004, 95% CI: [-0.109, 0.117], p=0.943; adjusted: β=-0.012, 95% CI: [-0.128, 0.104], p=0.836, Fig VD) was found.
Discussion

The main findings of the present study was that women homozygous for S in both polymorphisms studied had a four-fold higher chance of pregnancy compared to women homozygous for N in corresponding codons. It was also evident that carriers of S312 in the LHCGR more often became pregnant after IVF than those with N in the same position; 56% higher rate for heterozygous women with one S and 83% for homozygous women, compared to women homozygous for N. The same patterns were also present in women who had an embryo transferred. The main finding of the present study was also validated in an independent population of women, though not statistically significant, most probably due to a smaller number of women eligible than in the first study population. In the merged cohort, consisting of more than 600 women, relationships with pregnancies were even stronger than in the original cohort, and a linear association with pregnancy rate and increasing number of G alleles was noted.

Both FSH and LH are required for adequate oocyte maturation (Segaloff and Ascoli, 1993), and hence it is not surprising that variants of the LHCGR play a role in the outcome of IVF treatments. The mechanism underlying is unknown, but it has been proposed that G protein-coupled receptors may form homo- and heterodimers (Angers et al., 2002), so that stimulation by one of the hormones could be mediated in part through the other hormone’s receptor and that some isoforms of the different receptors may have beneficial function compared to other isoforms. Thus, the LHCGR genotype could influence the response to FSH stimulation. Still, many LH effects are considered as indirect since the distribution of LHCGR on granulosa cells is not as dense and stable as the FSHR distribution during the menstrual cycle (Camp et al., 1991). In the current work, an attempt to elucidate the mechanism behind the impact of combinations of
FSHR and LHCGR variants on receptor function was made by stimulating granulosa cells in vitro with Follitropin alpha and Menotropin, respectively. However, when analyzing a combination of the N680S of the FSHR and N312S of the LHCGR in vitro, no linear association between combined receptor variants and hormone sensitivity was detected. Nevertheless, granulosa cells from the group of women who were homozygous for N in both polymorphisms, comprising eight women, displayed a lower cAMP activity following Follitropin alpha stimulation when compared to women with other genotypes. Due to the limited sample size, this finding has yet to be regarded as preliminary, due to the fact that the cells used in the in vitro experiments were pre-stimulated during the IVF trial in the clinic, which could impact the results. The receptors on the granulosa cells may for example already have been down- or up-regulated to some extent, which could affect further stimulation with hormonal agents.

No differences in the number of follicles or oocytes between those carrying LHCGR N312 and S312 were found in the current study population, nor were there any obvious differences regarding embryo quality. Nevertheless, the pregnancy rates differed markedly. This could either be due to small differences in the maturation of the oocyte, not visible through light microscopy, and taking place after the hCG administration; or a problem that occurred at a later developmental stage, after embryo transfer. Since LH regulates the formation of corpus luteum, it could also be due to some insufficiency of this structure, which could affect its ability to produce hCG and progesterone, which is needed to support the hatching embryo. The large difference in pregnancy rates could also partly be an effect of differing stimulation protocols prior to IVF treatment, and we therefore adjusted for this factor in the analyses. Furthermore, when PCOS cases were removed from the analyses, the association with pregnancy rates became
stronger, indicating that the interplay between receptors and gonadotropins in this category of patients may be different than in other women. Women homozygous for LHCGR N312 also required lower doses of exogenous FSH for adequate response. Considering the dimerization hypothesis, this could indicate that N renders the receptor more hormone sensitive, which is consistent with earlier hypotheses (Piersma et al., 2007; Simoni et al., 2008). Several studies have also indicated that high LH levels (>10 IU/L) are associated with increased miscarriage rates and lower chances of pregnancy (Regan et al., 1990; Shoham et al., 1990), and it seems likely that a more sensitive LHCGR would have the same effect.

In the current study, the FSHR S680 genotype was beneficial for pregnancy outcome only if combined with LHCGR S312. There was no sign of influence of FSHR variants per se regarding receptor sensitivity, neither on clinical outcome in IVF trials nor on in vitro stimulation response, which was in contrast to previous reports (Perez Mayorga et al., 2000; Sudo et al., 2002; Jun et al., 2006; Casarini et al., 2014). This could at least partly be explained by differences in study populations, as one of the previously used study population was considerably smaller, only comprising 161 women (Perez Mayorga et al., 2000). Ethnic origin could also account for some differences (Sudo et al., 2002).

The strength of the study was the large cohort of consecutively enrolled patients. These women were hence not selected for the study, but an ordinary cohort of women visiting a fertility clinic. The findings can therefore be generally applied. Another strength was the purity of the granulosa cell material, which made it possible to compare in vitro results and clinical results within the same study population. A drawback of the study was that it was not recorded when in the
menstrual cycle the baseline reproductive hormones were obtained, which therefore not was possible to adjust for. These proceedings may have masked possible links between receptor genotype and gonadotropin concentrations.

Another weakness was that due to limited biological material, granulosa cells were not available for in vitro stimulation from all women.

In summary, in this large cohort of women, those homozygous for S in both studied polymorphisms had a four-fold increased chance of pregnancy compared to women homozygous for N; whereas only 10% of women with N in both genes became pregnant, 39% of those with S did. Thus, if used in IVF trials, these SNPs could be used as predictors for pregnancy outcome, at least in Caucasian populations.
Author's roles

Study design: IL, MB, LB, KU, YLG. Recruitment of patients and collection of patient data: EH, MBu, LB, ILe. Lab exp: IL, MB, KU, AD, LK, CC. Statistical analysis: IL, MB. Data interpretation: IL, MB, KU, AD, EH, SS, CYA, YLG. Writing of manuscript draft: IL, MB, AD, YLG. Final manuscript: all co-authors.

Acknowledgments

We thank Per-Anders Bertilsson, Department of Clinical Sciences, Cellular Autoimmunity Unit, Lund University, Malmö, Sweden, for excellent technical assistance and handling of the FACSAria.

The FACSAria was a donation from the Knut and Alice Wallenberg Foundation.

Funding

This work was supported by Interreg IV A, EU (grant 167158) and ALF governments grant (F2014/354). Merck-Serono (Darmstadt, Germany) supported the enrolment of the subjects.

Conflict of interest

The authors declare no conflict of interest.
References


Thomas RM, Nechamen CA, Mazurkiewicz JE, Ulloa-Aguirre A, Dias JA. The adapter protein APPL1 links FSH receptor to inositol 1,4,5-trisphosphate production and is implicated in intracellular Ca(2+) mobilization. *Endocrinology* 2011;152:1691-1701.


Figure legends

Figure I

Pregnancy frequencies for the LHCGR N312S and FSHR N680S polymorphisms. A) LHCGR N312S, all women in the study: N/N (n=67), N/S (n=175), S/S (n=131); B) LHCGR N312S, only women receiving ET: N/N (n=54), N/S (n=147), S/S (n=109); C) FSHR N680S, all women: N/N (n=102), N/S (n=206), S/S (n=65); D) FSHR N680S, ET: N/N (n=84), N/S (n=171), S/S (n=55).

Figure II

Pregnancy frequencies for combined genotypes. A) All women: LHCGR N312 in combination with FSHR N680, N680S, and S680 comprised n=20, n=35, and n=12 women, respectively. LHCGR N312S in combination with FSHR N680, N680S, and S680 comprised n=49, n=96, and n=30 women, respectively. LHCGR S312 in combination with FSHR N680, N680S, and S680 comprised n=33, n=75, and n=23 women, respectively. B) Only women receiving ET: LHCGR N312 in combination with FSHR N680, N680S, and S680 comprised n=18, n=27, and n=9 women, respectively. LHCGR N312S in combination with FSHR N680, N680S, and S680 comprised n=41, n=80, and n=26 women, respectively. LHCGR S312 in combination with FSHR N680, N680S, and S680 comprised n=25, n=64, and n=20 women, respectively.

Figure III

Pregnancy frequencies for combined genotypes in the merged population (n=606). A) All women. 0: n=30 women, 1: n=129 women, 2: n=243 women, 3: n=169 women, and 4: n=35 women. B) Only women receiving ET. 0: n=28 women, 1: n=109 women, 2: n=208 women, 3: n=151 women, and 4: n=31 women.
Figure IV
A) Unsorted sample: Granulosa cells with a mixture of squamous cells, small lymphocyte like cells, degenerated nuclei, and some debris. (Htx-eosin, 10×). B) Sorted sample: Virtually pure population of granulosa cells, dispersed or in loose clusters. The cells have pale cytoplasm with indistinct cell borders, round or ovoid, often eccentric nuclei with coarse but uniform chromatin. (Htx-eosin, 10×). C) A small cluster of granulosa cells (Htx-eosin, 100×).

Figure V
Granulosa cell response measured as cAMP concentration (A-B) and IP₃ concentration (C-D), stratified as number of G alleles combined (FSHR S680, LHCGR S312) stimulated with A&C) Follitropin alpha; B&D) Menotropin.
Table 1. Clinical parameters and IVF outcome.

<table>
<thead>
<tr>
<th></th>
<th>LHCGR N312S</th>
<th>FSHR N680S</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All</td>
<td>N/N</td>
</tr>
<tr>
<td>First cohort n (%)</td>
<td>373 (100)†</td>
<td>67 (18)#</td>
</tr>
<tr>
<td>Validation cohort n (%)</td>
<td>233 (100)</td>
<td>34 (15)</td>
</tr>
<tr>
<td>Merged</td>
<td>606 (100)</td>
<td>101 (17)</td>
</tr>
<tr>
<td>Age (years)†</td>
<td>32.0±3.8</td>
<td>31.2±3.6</td>
</tr>
<tr>
<td>Age (years)‡‡</td>
<td>32.3±3.9</td>
<td>33.2±3.9</td>
</tr>
<tr>
<td>Age (years)‡‡‡</td>
<td>32.1±3.8</td>
<td>31.8±3.8</td>
</tr>
<tr>
<td>BMI (kg/m²)†</td>
<td>23.6±3.0</td>
<td>23.8±3.0</td>
</tr>
<tr>
<td>Endometriosis‡</td>
<td>26 (6.9)</td>
<td>4 (6.0)</td>
</tr>
<tr>
<td>PCOS‡</td>
<td>13 (3.5)</td>
<td>2 (3.0)</td>
</tr>
<tr>
<td>FSH baseline†</td>
<td>6.34 (2.7)</td>
<td>6.26 (2.3)</td>
</tr>
<tr>
<td>LH baseline†</td>
<td>9.56 (11)</td>
<td>9.32 (11)</td>
</tr>
<tr>
<td>E² baseline‡</td>
<td>419 (318)</td>
<td>415 (342)</td>
</tr>
<tr>
<td>Cycle length (days)†</td>
<td>28.9±2.9</td>
<td>29.4±2.7</td>
</tr>
<tr>
<td>Total dose FSH (IU)†</td>
<td>1699±781</td>
<td>1546±827</td>
</tr>
<tr>
<td>Total dose FSH (IU)‡‡</td>
<td>2059±884</td>
<td>2342±873</td>
</tr>
<tr>
<td>Total dose FSH (IU)‡‡‡</td>
<td>1837±840</td>
<td>1814±920</td>
</tr>
<tr>
<td>Daily FSH dose (IU)†</td>
<td>161±51</td>
<td>148±47</td>
</tr>
</tbody>
</table>

* p < 0.05, ** p < 0.01, † p < 0.001, †† p < 0.001, ‡ p < 0.05, ‡‡ p < 0.01, § p < 0.001, §§ p < 0.001.
<table>
<thead>
<tr>
<th></th>
<th>Validation cohort</th>
<th>Merged cohort</th>
<th>Merged cohort</th>
<th>FSH baseline data n=343 and cycle length data n=336</th>
<th>FSH baseline data n=58 and cycle length data n=60</th>
<th>FSH baseline data n=162 and cycle length data n=157</th>
<th><strong>FSH baseline data</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Number of follicles</strong>†</td>
<td>11.7±6.1</td>
<td>12.0±5.3</td>
<td>11.3±6.5</td>
<td>12.1±5.9</td>
<td>0.168</td>
<td>0.144</td>
<td>12.2±6.8</td>
</tr>
<tr>
<td></td>
<td>12.8±7.3</td>
<td>11.6±6.9</td>
<td>12.3±6.5</td>
<td>12.7±8.1</td>
<td>0.598</td>
<td>0.675</td>
<td>12.6±7.5</td>
</tr>
<tr>
<td></td>
<td>13.0±6.6</td>
<td>11.8±5.8</td>
<td>11.6±6.5</td>
<td>12.4±6.9</td>
<td>0.633</td>
<td>0.557</td>
<td>12.4±7.1</td>
</tr>
<tr>
<td></td>
<td>12.0±6.5</td>
<td>11.6±6.5</td>
<td>12.4±6.9</td>
<td>12.1±5.9</td>
<td>0.016</td>
<td>0.014</td>
<td>12.5±6.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mature oocytes</strong>†</td>
<td>9.00±5.6</td>
<td>9.09±5.2</td>
<td>8.71±5.8</td>
<td>9.21±5.5</td>
<td>0.457</td>
<td>0.397</td>
<td>9.25±6.0</td>
</tr>
<tr>
<td></td>
<td>10.5±6.8</td>
<td>10.0±6.4</td>
<td>10.5±6.6</td>
<td>10.8±7.2</td>
<td>0.947</td>
<td>0.935</td>
<td>11.3±7.1</td>
</tr>
<tr>
<td></td>
<td>11.7±6.5</td>
<td>11.8±6.5</td>
<td>11.6±6.5</td>
<td>12.4±6.9</td>
<td>0.740</td>
<td>0.717</td>
<td>10.1±6.5</td>
</tr>
<tr>
<td></td>
<td>9.57±6.1</td>
<td>9.34±6.2</td>
<td>9.93±6.3</td>
<td>9.93±6.3</td>
<td>0.740</td>
<td>0.717</td>
<td>9.43±6.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>GQE/oocyte</strong>†</td>
<td>0.21±0.18</td>
<td>0.19±0.18</td>
<td>0.21±0.19</td>
<td>0.20±0.17</td>
<td>0.997</td>
<td>0.900</td>
<td>0.20±0.18</td>
</tr>
<tr>
<td></td>
<td>0.25±0.22</td>
<td>0.20±0.14</td>
<td>0.26±0.24</td>
<td>0.26±0.22</td>
<td>0.358</td>
<td>0.348</td>
<td>0.26±0.23</td>
</tr>
<tr>
<td></td>
<td>0.22±0.20</td>
<td>0.20±0.16</td>
<td>0.23±0.21</td>
<td>0.22±0.19</td>
<td>0.559</td>
<td>0.549</td>
<td>0.22±0.20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Embryo transfer</strong>‡</td>
<td>310 (83)</td>
<td>54 (81)</td>
<td>147 (84)</td>
<td>109 (83)</td>
<td>0.818</td>
<td>-</td>
<td>84 (82)</td>
</tr>
<tr>
<td></td>
<td>212 (91)</td>
<td>31 (91)</td>
<td>91 (90)</td>
<td>90 (92)</td>
<td>0.912</td>
<td>-</td>
<td>74 (94)</td>
</tr>
<tr>
<td></td>
<td>522 (86)</td>
<td>85 (84)</td>
<td>238 (86)</td>
<td>199 (87)</td>
<td>0.801</td>
<td>-</td>
<td>158 (87)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical pregnancy</strong>‡</td>
<td>104 (28)</td>
<td>12 (18)</td>
<td>49 (28)</td>
<td>43 (33)</td>
<td>0.086</td>
<td>-</td>
<td>26 (25)</td>
</tr>
<tr>
<td></td>
<td>60 (26)</td>
<td>6 (18)</td>
<td>25 (25)</td>
<td>29 (30)</td>
<td>0.372</td>
<td>-</td>
<td>17 (22)</td>
</tr>
<tr>
<td></td>
<td>164 (27)</td>
<td>18 (18)</td>
<td>74 (27)</td>
<td>72 (31)</td>
<td>0.037*</td>
<td>-</td>
<td>43 (24)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Clinical pregnancy/ET</strong></td>
<td>0.34</td>
<td>0.22</td>
<td>0.33</td>
<td>0.39</td>
<td>0.090</td>
<td>-</td>
<td>0.31</td>
</tr>
<tr>
<td></td>
<td>0.28</td>
<td>0.19</td>
<td>0.27</td>
<td>0.32</td>
<td>0.380</td>
<td>-</td>
<td>0.23</td>
</tr>
<tr>
<td></td>
<td>0.31</td>
<td>0.21</td>
<td>0.31</td>
<td>0.36</td>
<td>0.044*</td>
<td>-</td>
<td>0.27</td>
</tr>
</tbody>
</table>

1 Validation cohort; 2 merged cohort; * p<0.05; † mean±sd; § adjusted values; ‡ n (%); †† FSH baseline data n=343 and cycle length data n=336; ††† FSH baseline data n=58 and cycle length data n=60; †††† FSH baseline data n=162 and cycle length data n=157; ** FSH baseline
data \( n=123 \) and cycle length data \( n=119 \); †† FSH baseline data \( n=94 \) and cycle length data \( n=88 \); †† FSH baseline data \( n=190 \) and cycle length data \( n=190 \); §§ FSH baseline data \( n=59 \) and cycle length data \( n=58 \).
Table II. Stimulation protocols.

<table>
<thead>
<tr>
<th></th>
<th>Stimulated patients, n (%)</th>
<th>Short protocol, n (%)</th>
<th>Mean total dose ±sd (IU)</th>
<th>Mean daily dose ±sd (IU)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All patients</td>
<td>384 (100%)</td>
<td>207 (54%)</td>
<td>1695±775</td>
<td>160±51</td>
</tr>
<tr>
<td>Follitropin alpha</td>
<td>275 (72%)</td>
<td>156 (57%)</td>
<td>1672±720</td>
<td>158±47</td>
</tr>
<tr>
<td>Follitropin beta</td>
<td>76 (20%)</td>
<td>37 (49%)</td>
<td>1605±737</td>
<td>186±72</td>
</tr>
<tr>
<td>Urofollitropin</td>
<td>21 (5%)</td>
<td>11 (52%)</td>
<td>1908±1021</td>
<td>152±45</td>
</tr>
<tr>
<td>Menotropin</td>
<td>11 (3%)</td>
<td>2 (18%)</td>
<td>2617±1119</td>
<td>224±75</td>
</tr>
</tbody>
</table>
Table III. Microscope phenotyping of isolated granulosa cells in unsorted and sorted patient material (n=3).

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Specimen 1</th>
<th>Specimen 2</th>
<th>Specimen 3</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unsorted</td>
<td>Sorted</td>
<td>Unssorted</td>
</tr>
<tr>
<td>Granulosa cells</td>
<td>200</td>
<td>291</td>
<td>211</td>
</tr>
<tr>
<td>Other cells*</td>
<td>94</td>
<td>9</td>
<td>99</td>
</tr>
<tr>
<td>Total</td>
<td>294</td>
<td>300</td>
<td>310</td>
</tr>
<tr>
<td>% granulosa cells</td>
<td>66.6</td>
<td>97.0</td>
<td>68.1</td>
</tr>
</tbody>
</table>

\*Degenerated cells and stripped nuclei, small lymphocyte like cells, and squamous cells against a background of debris.
Table IV. Granulosa cell response *in vitro*, presented as mean±sd.

<table>
<thead>
<tr>
<th>Genotype</th>
<th>LHCGR N312S</th>
<th>N/N</th>
<th>N/S</th>
<th>S/S</th>
<th>Slope#</th>
<th>95% CI#</th>
<th>p</th>
<th>p#</th>
</tr>
</thead>
<tbody>
<tr>
<td>Menotropin</td>
<td>pmol cAMP / mg protein (n=102)</td>
<td>26.0±31.3</td>
<td>21.8±30.3</td>
<td>34.4±73.2</td>
<td>-0.178</td>
<td>[-0.55, 0.19]</td>
<td>0.482</td>
<td>0.343</td>
</tr>
<tr>
<td></td>
<td>pg IP₃/ mg protein (n=49)</td>
<td>1.33±0.52</td>
<td>1.26±0.43</td>
<td>1.37±0.53</td>
<td>0.051</td>
<td>[-0.09, 0.20]</td>
<td>0.746</td>
<td>0.479</td>
</tr>
<tr>
<td>Follitropin alpha</td>
<td>pmol cAMP / mg protein (n=119)</td>
<td>24.3±56.5</td>
<td>22.4±37.7</td>
<td>52.7±104</td>
<td>0.372</td>
<td>[-0.05, 0.80]</td>
<td>0.089</td>
<td>0.084</td>
</tr>
<tr>
<td></td>
<td>pg IP₃/ mg protein (n=55)</td>
<td>1.20±0.38</td>
<td>1.21±0.38</td>
<td>1.30±0.37</td>
<td>0.073</td>
<td>[-0.10, 0.24]</td>
<td>0.411</td>
<td>0.394</td>
</tr>
<tr>
<td>FSHR N680S</td>
<td>N/N</td>
<td>N/S</td>
<td>S/S</td>
<td>Slope#</td>
<td>95% CI#</td>
<td>p</td>
<td>p#</td>
<td></td>
</tr>
<tr>
<td>Menotropin</td>
<td>pmol cAMP / mg protein (n=102)</td>
<td>22.8±39.3</td>
<td>25.2±32.4</td>
<td>49.5±108</td>
<td>0.095</td>
<td>[-0.31, 0.50]</td>
<td>0.687</td>
<td>0.639</td>
</tr>
<tr>
<td></td>
<td>pg IP₃/ mg protein (n=49)</td>
<td>1.34±0.45</td>
<td>1.31±0.52</td>
<td>1.24±0.47</td>
<td>-0.035</td>
<td>[-0.19, 0.12]</td>
<td>0.654</td>
<td>0.643</td>
</tr>
<tr>
<td>Follitropin alpha</td>
<td>pmol cAMP / mg protein (n=119)</td>
<td>25.5±55.7</td>
<td>35.4±58.3</td>
<td>44.6±128</td>
<td>0.077</td>
<td>[-0.38, 0.54]</td>
<td>0.727</td>
<td>0.738</td>
</tr>
<tr>
<td></td>
<td>pg IP₃/ mg protein (n=55)</td>
<td>1.27±0.32</td>
<td>1.21±0.44</td>
<td>1.25±0.33</td>
<td>-0.031</td>
<td>[-0.20, 0.14]</td>
<td>0.714</td>
<td>0.716</td>
</tr>
</tbody>
</table>

*= adjusted for age*
Stimulation response (pmol cAMP/mg protein, ln-scale)

Number of G alleles

Stimulation response (pg IP_3/mg protein, ln-scale)

Number of G alleles